Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-cash Items (2016 - 2017)

Historic Non-cash Items for Agios Pharmaceuticals (AGIO) over the last 6 years, with Q1 2017 value amounting to $2.9 million.

  • Agios Pharmaceuticals' Non-cash Items rose 2726.98% to $2.9 million in Q1 2017 from the same period last year, while for Mar 2017 it was $2.9 million, marking a year-over-year increase of 2726.98%. This contributed to the annual value of $63.6 million for FY2016, which is 290386.83% up from last year.
  • Agios Pharmaceuticals' Non-cash Items amounted to $2.9 million in Q1 2017, which was up 2726.98% from $63.6 million recorded in Q4 2016.
  • Over the past 5 years, Agios Pharmaceuticals' Non-cash Items peaked at $360.9 million during Q4 2014, and registered a low of $1.6 million during Q3 2014.
  • Over the past 5 years, Agios Pharmaceuticals' median Non-cash Items value was $74.8 million (recorded in 2013), while the average stood at $85.7 million.
  • Examining YoY changes over the last 5 years, Agios Pharmaceuticals' Non-cash Items showed a top increase of 1064539.35% in 2015 and a maximum decrease of 9857.67% in 2015.
  • Over the past 5 years, Agios Pharmaceuticals' Non-cash Items (Quarter) stood at $76.2 million in 2013, then soared by 373.74% to $360.9 million in 2014, then plummeted by 57.45% to $153.6 million in 2015, then tumbled by 58.61% to $63.6 million in 2016, then plummeted by 95.42% to $2.9 million in 2017.
  • Its Non-cash Items stands at $2.9 million for Q1 2017, versus $63.6 million for Q4 2016 and $110.1 million for Q3 2016.